Low-dose intradermal mRNA-1273 boosting vaccine following BBiBP-CorV vaccination during the omicron pandemics

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-06-04 DOI:10.1016/j.vaccine.2025.127330

Warawut Chaiwong , Nuchjira Takheaw , Witida Laopajon , Chote Nisoong , Supansa Pata , Pilaiporn Duangjit , Juthamas Inchai , Chaicharn Pothirat , Chaiwat Bumroongkit , Athavudh Deesomchok , Theerakorn Theerakittikul , Atikun Limsukon , Pattraporn Tajarernmuang , Nutchanok Niyatiwatchanchai , Konlawij Trongtrakul , Watchara Kasinrerk , Chalerm Liwsrisakun

{"title":"Low-dose intradermal mRNA-1273 boosting vaccine following BBiBP-CorV vaccination during the omicron pandemics","authors":"Warawut Chaiwong , Nuchjira Takheaw , Witida Laopajon , Chote Nisoong , Supansa Pata , Pilaiporn Duangjit , Juthamas Inchai , Chaicharn Pothirat , Chaiwat Bumroongkit , Athavudh Deesomchok , Theerakorn Theerakittikul , Atikun Limsukon , Pattraporn Tajarernmuang , Nutchanok Niyatiwatchanchai , Konlawij Trongtrakul , Watchara Kasinrerk , Chalerm Liwsrisakun","doi":"10.1016/j.vaccine.2025.127330","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Long-term kinetics of the neutralizing antibody (NAb) response against Omicron using 1/10 intradermal (ID) mRNA vaccination as a booster following a complete series of inactivated vaccines, as well as its safety are still limited. Therefore, the objective of this study was to compare local and systemic reactions, NAb levels against Omicron BA.2 and BA.4/5 after four weeks of boosting, and durability of NAb against BA.2 and BA.4/5 after 12 and 24 weeks of mRNA-1273 vaccine boosting among the 1/10 ID, 1/5 ID, and full-dose IM groups in subjects who received a standard primary series of the BBIBP-CorV vaccine.</div></div><div><h3>Methods</h3><div>Two-week side effects and baseline, 4-week, 12-week and 24-week NAb levels against wild type, BA.2 and BA.4/5 Omicron among 3 groups were compared.</div></div><div><h3>Results</h3><div>There were 140 participants with 46, 47, and 47 subjects in 1/10 ID, 1/5 ID, and IM groups, respectively. The 1/10 ID-induced localized pain is less common than IM and 1/5 ID. Systemic reactions were lower than IM and comparable to 1/5 ID. BA.2 NAb was indifferent from the other 2 groups, except 2.5-fold lower than IM at 12 weeks. BA.2 NAb in 1/10 ID was higher than the cut-off level throughout the 24-week study period whereas BA.4/5 NAb at 24 weeks was below the NAb detection threshold and significantly lower than IM group.</div></div><div><h3>Conclusion</h3><div>The 1/10 ID mRNA-1273 boosting after BBIBP-CorV priming was safe and induced above-threshold NAb against BA.2 and BA.4/5 for at least 12 weeks.</div></div><div><h3>Clinical trials registry</h3><div>This study was registered to the Thai Clinical Trials Registry with study ID: TCTR20210822002.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127330"},"PeriodicalIF":4.5000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25006279","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Long-term kinetics of the neutralizing antibody (NAb) response against Omicron using 1/10 intradermal (ID) mRNA vaccination as a booster following a complete series of inactivated vaccines, as well as its safety are still limited. Therefore, the objective of this study was to compare local and systemic reactions, NAb levels against Omicron BA.2 and BA.4/5 after four weeks of boosting, and durability of NAb against BA.2 and BA.4/5 after 12 and 24 weeks of mRNA-1273 vaccine boosting among the 1/10 ID, 1/5 ID, and full-dose IM groups in subjects who received a standard primary series of the BBIBP-CorV vaccine.

Methods

Two-week side effects and baseline, 4-week, 12-week and 24-week NAb levels against wild type, BA.2 and BA.4/5 Omicron among 3 groups were compared.

Results

There were 140 participants with 46, 47, and 47 subjects in 1/10 ID, 1/5 ID, and IM groups, respectively. The 1/10 ID-induced localized pain is less common than IM and 1/5 ID. Systemic reactions were lower than IM and comparable to 1/5 ID. BA.2 NAb was indifferent from the other 2 groups, except 2.5-fold lower than IM at 12 weeks. BA.2 NAb in 1/10 ID was higher than the cut-off level throughout the 24-week study period whereas BA.4/5 NAb at 24 weeks was below the NAb detection threshold and significantly lower than IM group.

Conclusion

The 1/10 ID mRNA-1273 boosting after BBIBP-CorV priming was safe and induced above-threshold NAb against BA.2 and BA.4/5 for at least 12 weeks.

Clinical trials registry

This study was registered to the Thai Clinical Trials Registry with study ID: TCTR20210822002.

查看原文本刊更多论文

在大流行期间接种BBiBP-CorV疫苗后，低剂量皮内mRNA-1273增强疫苗

背景：在一系列完整的灭活疫苗后，使用1/10皮内（ID） mRNA疫苗作为增强剂，对Omicron的中和抗体（NAb）反应的长期动力学及其安全性仍然有限。因此，本研究的目的是比较1/10 ID组、1/5 ID组和全剂量IM组在接受标准初级系列BBIBP-CorV疫苗的受试者中，局部和全身反应、4周增强后对Omicron ba2和ba4 /5的NAb水平，以及12周和24周增强mRNA-1273疫苗后NAb对ba2和ba4 /5的持久性。方法比较3组患者2周毒副作用及基线、4周、12周、24周抗野生型、BA.2和BA.4/5欧米克隆抗体水平。结果1/10 ID组、1/5 ID组、IM组共140人，分别为46人、47人、47人。1/10 ID引起的局部疼痛较IM和1/5 ID少见。全身反应低于IM，与1/5 ID相当。BA.2 NAb与其他两组无显著差异，但在12周时比IM低2.5倍。在整个24周的研究期间，1/10 ID组BA.2 NAb高于临界值，而24周时BA.4/5 NAb低于NAb检测阈值，且显著低于IM组。结论BBIBP-CorV引物后1/10 ID mRNA-1273的增强是安全的，可诱导BA.2和BA.4/5高于阈值的NAb至少持续12周。临床试验注册本研究在泰国临床试验注册中心注册，研究编号：TCTR20210822002。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.